Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.

How to buy Lipocine stock

Own Lipocine stock in just a few minutes.

Lipocine Inc is a biotechnology business based in the US. Lipocine shares (LPCN) are listed on the NASDAQ and all prices are listed in US Dollars. Lipocine employs 11 staff and has a market cap (total outstanding shares value) of 0.00.

How to buy shares in Lipocine

  1. Compare share trading platforms. Use our comparison table to help you find a platform that fits you.
  2. Open your brokerage account. Complete an application with your details.
  3. Confirm your payment details. Fund your account.
  4. Research the stock. Find the stock by name or ticker symbol – LPCN – and research it before deciding if it's a good investment for you.
  5. Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
  6. Check in on your investment. Optimize your portfolio by tracking your stock.

Lipocine share price

Use our graph to track the performance of LPCN stocks over time.

Lipocine shares at a glance

Information last updated 2021-04-30.
52-week range$0.55 - $2.42
50-day moving average $1.53
200-day moving average $1.55
Wall St. target price$5.33
PE ratio N/A
Dividend yield N/A (0%)
Earnings per share (TTM) $-0.55

Buy Lipocine shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
Name Product Stock trade fee Asset types Option trade fee Annual fee Signup bonus
Robinhood
$0
Stocks, Options, ETFs
$0
0%
Free stock (chosen randomly with a value anywhere between $2.50 and $200)
Sign up using the "go to site" link
Make unlimited commission-free trades in stocks, funds, and options with Robinhood Financial.
Interactive Brokers
$0
Stocks, Bonds, Options, Mutual funds, ETFs, Currencies
$0 + $0.65/contract, $1 minimum
0%
N/A
IBKR Lite offers $0 commissions, and IBKR Pro offers advanced tools for professional traders.
Sofi Invest
$0
Stocks, ETFs, Cryptocurrency
N/A
0%
Get one free stock worth up to $1,000
Open an account
A free way to invest in stocks, ETFs and crypto.
Webull
$0
Stocks, Options, ETFs
$0
0%
Get one free stock valued between $2.50 and $250 when you open an account, one more with a deposit
Open an account
Margin financing rates start at 3.99%. No monthly subscription fees for margin.
Public
$0
Stocks, ETFs
N/A
$0 per month
N/A
loading

Compare up to 4 providers

*Signup bonus information updated weekly.

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy Lipocine stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Lipocine financials

Gross profit TTM $-5,053,695
Return on assets TTM -49.98%
Return on equity TTM -193.85%
Profit margin 0%
Book value $0.22
Market capitalisation $126.3 million

TTM: trailing 12 months

Shorting Lipocine shares

There are currently 3.5 million Lipocine shares held short by investors – that's known as Lipocine's "short interest". This figure is 14.5% down from 4.1 million last month.

There are a few different ways that this level of interest in shorting Lipocine shares can be evaluated.

Lipocine's "short interest ratio" (SIR)

Lipocine's "short interest ratio" (SIR) is the quantity of Lipocine shares currently shorted divided by the average quantity of Lipocine shares traded daily (recently around 4.1 million). Lipocine's SIR currently stands at 0.86. In other words for every 100,000 Lipocine shares traded daily on the market, roughly 860 shares are currently held short.

However Lipocine's short interest can also be evaluated against the total number of Lipocine shares, or, against the total number of tradable Lipocine shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Lipocine's short interest could be expressed as 0.04% of the outstanding shares (for every 100,000 Lipocine shares in existence, roughly 40 shares are currently held short) or 0.0404% of the tradable shares (for every 100,000 tradable Lipocine shares, roughly 40 shares are currently held short).

Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Lipocine.

Find out more about how you can short Lipocine stock.

Lipocine share dividends

We're not expecting Lipocine to pay a dividend over the next 12 months.

Have Lipocine's shares ever split?

Lipocine's shares were split on a 1:100 basis on 24 July 2013. So if you had owned 100 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Lipocine shares – just the quantity. However, indirectly, the new 9900% higher share price could have impacted the market appetite for Lipocine shares which in turn could have impacted Lipocine's share price.

Lipocine share price volatility

Over the last 12 months, Lipocine's shares have ranged in value from as little as $0.5479 up to $2.42. A popular way to gauge a stock's volatility is its "beta".

LPCN.US volatility(beta: 0.53)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Lipocine's is 0.5312. This would suggest that Lipocine's shares are less volatile than average (for this exchange).

Lipocine overview

Lipocine Inc. , a clinical-stage biopharmaceutical company, focuses on the development of pharmaceutical products for the treatment of metabolic and endocrine disorders. Its primary development programs are based on oral delivery solutions for poorly bioavailable drugs. The company has a portfolio of product candidates designed to produce pharmacokinetic characteristics and facilitate lower dosing requirements, bypass first-pass metabolism in certain cases, reduce side effects, and eliminate gastrointestinal interactions that limit bioavailability. Its lead product candidate is TLANDO, an oral testosterone replacement therapy. The company's pipeline candidates also include LPCN 1144, an oral prodrug of bioidentical testosterone that is in Phase II Clinical trial for the treatment of non-cirrhotic non-alcoholic steatohepatitis (NASH); TLANDO XR, an oral prodrug of testosterone for once daily dosing, which has completed Phase II clinical trial in hypogonadal men; LPCN 1148, an oral prodrug of bioidentical testosterone that has completed phase I clinical trial for the treatment of NASH cirrhosis; and LPCN 1107, an oral hydroxyprogesterone caproate product that has completed dose finding Phase II clinical trial for the prevention of recurrent preterm birth. The company is headquartered in Salt Lake City, Utah.

Frequently asked questions

More guides on Finder

Ask an Expert

You are about to post a question on finder.com:

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • finder.com is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked

Finder.com provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and finder.com Terms of Use.

Questions and responses on finder.com are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site